SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?


To: DewDiligence_on_SI who wrote (2511)9/20/2010 10:06:45 AM
From: Arthur Radley  Respond to of 3027
 
thestreet.com

Maybe this meeting will finally resolve any outstanding issues.........



To: DewDiligence_on_SI who wrote (2511)9/25/2010 4:46:35 PM
From: DewDiligence_on_SI  Read Replies (1) | Respond to of 3027
 
MNTA ‘ReadMeFirst’ updated:

despite what Teva says, US Copaxone patents expire May 2014 (not Sep 2015);
according to NVS, Lovenox is highest-margin product in Sandoz’s portfolio;
FDA approves NVS’ Gilenya for first-line RRMS;
musings on Gilenya’s commercial prospects;
Merck KGaA’s Cladribine rejected in EU;
index to FDA labels of approved MS drugs;
new version of “What’s New in the Anticoagulant Market.”


siliconinvestor.com